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Abstract: The ageing brain is characterised by changes at the physical, histological, biochemical and
physiological levels. This ageing process is associated with an increased risk of developing a number
of neurological disorders, notably Alzheimer’s disease and Parkinson’s disease. There is evidence
that mitochondrial dysfunction and oxidative stress play a key role in the pathogenesis of such
disorders. In this article, we review the potential therapeutic role in these age-related neurological
disorders of supplementary coenzyme Q10, a vitamin-like substance of vital importance for normal
mitochondrial function and as an antioxidant. This review is concerned primarily with studies in
humans rather than in vitro studies or studies in animal models of neurological disease. In particular,
the reasons why the outcomes of clinical trials supplementing coenzyme Q10 in these neurological
disorders is discussed.
Keywords: coenzyme Q10; Alzheimer’s disease; Parkinson’s disease; amyotrophic lateral sclerosis;
stroke; multiple system atrophy; ophthalmic disorders; neurodegenerative disorders; ageing
1. Introduction
The ageing brain is characterised by changes at the physical, histological, biochemical
and physiological levels. At the physical level, the volume of the brain shrinks with
increasing age; this process appears to begin after the age of forty and is particularly
marked after the age of seventy [1]. Different areas of the brain may be differentially affected
by this shrinkage process, with the prefrontal cortex (associated with complex cognitive
behaviour) being particularly susceptible [2]. At the histological level, the volumes of
both white and grey matter are reduced with increasing age [3]. Whilst the number
of neuronal cells may not be significantly reduced during normal ageing, neurons may
undergo shrinkage, with a reduction in axonal length, degeneration of the myelin sheath
and reduced numbers of synaptic contacts [4]. Similarly, whilst numbers of glial cells may
not be significantly reduced with ageing, the supportive role of astrocytes, oligodenrocytes
and microglia may compromised, rendering neurons more susceptible to damage [5]. At
the biochemical level, ageing is characterised by reductions in the levels of a number of
neurotransmitters, including acetylcholine, dopamine and serotonin [6]. In addition, there
is evidence of mitochondrial dysfunction in brain tissue with increasing age, both with
regard to energy production and to increased generation of free radical species [7]. Cellular
damage resulting from free radical-induced oxidative stress has been implicated in both
normal ageing and in various neurodegenerative disorders [8]. At the physiological level,
cognitive function is affected by ageing, particularly the speed of information processing
and memory [9]. In addition, the blood supply to the ageing brain may be impaired [10]
and there is evidence for partial breakdown of the blood–brain barrier [11]. This review
is concerned primarily with studies in humans rather than in vitro studies or studies in
animal models of neurological disease. In particular, the reasons why the outcomes of
clinical trials supplementing coenzyme Q10 in these neurological disorders is discussed.
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2. Neurological Disorders and Ageing
Ageing is associated with an increased risk of developing a number of neurologi-
cal disorders, including dementia (Alzheimer’s disease, vascular dementia), Parkinson’s
disease, amyotrophic lateral sclerosis (ALS) and stroke. Thus, the risk of developing the
progressive neurodegenerative disorder Alzheimer’s disease (which accounts for approx-
imately 75% of all dementia cases) increases from approximately 6% at age 65 to 36% at
age 85 [12]. Similarly, the risk of developing Parkinson’s disease is less than 1% at age 60
and 5% at age 85 [13]. ALS is relatively uncommon before the age of forty but increases
exponentially thereafter; the age of onset is typically in the range 55–75 years, with a
peak incidence in those aged 70–80 years [14]. With regard to strokes, the risk doubles
with every decade after 50 years of age, affecting approximately 20% of the population at
age 75 years [15]. Such age-related neurological disorders represent a burden to patients
and their carers and to health and social services. Thus, in the UK, patients with these
neurological disorders are rated to have the lowest health-related quality of life, whilst
these conditions consume a significant proportion of the NHS and social services bud-
gets (www.england.nhs.neurologicalconditions.uk, accessed on 11 November 2021). For
example, the annual cost of dementia to the NHS is approximately 4 billion GBP, with
corresponding social care costs of approximately 10 billion GBP. In addition, the annual cost
of strokes to the NHS is approximately 3 billion GBP and Parkinson’s disease more than
200 million GBP, respectively. Other neurological disorders with age-associated increased
risk include multiple system atrophy and some forms of ataxia, as well as sensory disorders,
such as glaucoma, macular degeneration and presbycusis (hearing loss).
3. Coenzyme Q10 and Ageing
Coenzyme Q10 (CoQ10) is a vitamin-like substance synthesised in most tissues of
the human body. CoQ10 has a key role in the process of cellular energy supply via
oxidative phosphorylation within mitochondria, shuttling electrons from complexes I and
II to complex III of the mitochondrial respiratory chain (MRC; Figure 1); CoQ10 is also a
powerful lipid-soluble antioxidant, protecting cell membranes from free radical-induced
oxidative damage [16]. In addition to its role in mitochondrial function, CoQ10 is present
in other subcellular organelles, including lysosomes, peroxisomes, Golgi apparatus and
endoplasmic reticulum. As well as providing antioxidant protection for these organelle
membranes from oxidative stress, CoQ10 has a role in maintaining the intralysosomal
pH [17]. CoQ10 has been shown to directly affect the expression of a number of genes,
including those involved in the inflammatory process [18]. Although a small amount of
CoQ10 (of the order of 5 mg/day) is obtained from the normal diet [19], most of the body’s
daily CoQ10 requirement is derived from endogenous synthesis. The daily requirement for
CoQ10 is not known with certainty but has been estimated to be approximately 500 mg/day,
based on a total body pool of 2000 mg and an average tissue turnover time of 4 days [19].
In humans, CoQ10 levels are typically measured in blood samples, although there
is some discussion as to how accurately blood CoQ10 levels reflect those within other
tissues; CoQ10 levels may, therefore, be measured in muscle biopsy specimens although
less frequently [20]. In view of the preponderance of neurological dysfunction associated
with a deficit in CoQ10 status, it would seem appropriate to determine patient cerebral
CoQ10 status. Cerebral spinal fluid (CSF) has been suggested as an appropriate surrogate
to use in order to evaluate cerebral CoQ10 status [20]. In view of the low levels of CoQ10
reported in this matrix, only highly sensitive analytical techniques, such as HPLC-ED
(electrochemical detection) and tandem mass spectrometry, would appear appropriate for
this analysis due to their low detection limits [20]. A tentative reference range of 5.7–9.0 nM
has been established for CSF CoQ10 status in humans [21].
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Figure 1. Diagram of the mitochondrial respiratory chain (MRC) showing the enzyme complexes I 
V and the electron carriers’ coenzyme Q10 (CoQ10), cytochrome c (C) and protons (H+). 
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decline that may vary in different tissues [22]. For example, in heart tissue, the production 
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comparable data for changes in CoQ10 levels in the human brain as a function of normal 
ageing. CoQ10 is of relevance to normal neurological function and the risk of developing 
neurological disorders on the basis of the high-energy requirement (equivalent to 20% of 
total body energy consumption) for normal brain function and the implication of mito-
chondrial dysfunction and free radical-induced oxidative stress in the pathogenesis of a 
number of neurological disorders. Coenzyme Q10 is present in all areas of the brain [23]; 
both neurons and glia contain CoQ10, and supplemental CoQ10 has been shown to restore 
depleted levels in cultured human neuronal cells [24]. The age-related changes in neuro-
logical function and increased risk of developing neurological disorders are paralleled by 
the age-related depletion of tissue CoQ10 levels. The question, therefore, arises as to 
whether supplementation with CoQ10 could address these issues, and this is discussed in 
the following sections. To date, there have been no randomised controlled trials to assess 
the benefit of CoQ10 supplementation on cognitive function in the normal elderly. How-
ever, a 90-day randomised controlled trial has now been registered with the Australian 
and New Zealand Clinical Trials Registry (ANZCTRN12618001841268) to assess the abil-
ity of ubiquinol supplementation to ameliorate cognitive decline in healthy male and fe-
male volunteers aged 60 and above. This study will be the first of its kind to investigate 
Figure 1. Diagram of the mitochondrial respiratory chain (MRC) showing the enzyme complexes I V
and the electron carriers’ coenzyme Q10 (CoQ10), cytochrome c (C) and protons (H+).
Relatively little data are available in the published literature regarding changes in
CoQ10 levels in various human tissues as a function of age. However, in general terms,
optimum CoQ10 production occurs around 25 years of age, with a subsequent age-related
decline that may vary in different tissues [22]. For example, in heart tissue, the production
of CoQ10 at age 65 is approximately half of that at age 25 years. At present, there is no
comparable data for changes in CoQ10 levels in the human brain as a function of normal
ageing. CoQ10 is of relevance to normal neurological function and the risk of developing
neurological disorders on the basis of the high-energy requirement (equivalent to 20% of
total body energy consumption) for normal brain function and the implication of mito-
chondrial dysfunction and free radical-induced oxidative stress in the pathogenesis of a
number of neurological disorders. Coenzyme Q10 is present in all areas of the brain [23];
both neurons and glia contain CoQ10, and supplemental CoQ10 has been shown to restore
depleted levels in cultured human neuronal cells [24]. The age-related changes in neu-
rological function and increased risk of developing neurological disorders are paralleled
by the age-related depletion of tissue CoQ10 levels. The question, therefore, arises as to
whether supplementation with CoQ10 could address these issues, and this is discussed
in the following sections. To date, there have been no randomised controlled trials to
assess the benefit of CoQ10 supplementation on cognitive function in the normal elderly.
However, a 90-day randomised controlled trial has now been registered with the Australian
and New Zealand Clinical Trials Registry (ANZCTRN12618001841268) to assess the ability
of ubiquinol supplementation to ameliorate cognitive decline in healthy male and female
volu teers aged 60 and above. This study will be the first of its kind to investigate the
potential of ubiquinol treatment to arrest the age-related cognitive decline, and its results
are awaited with anticipation.
4. Coenzyme Q10 and Neurological Disorders
Alzheimer’s isease: Alzheim r’s diseas (AD) is a progressive neurodegen rative
disorder charact rised by initial memory impairment and cognitive decline. AD generally
presents after th age of 65 years, although there are cases of AD tha present before this
age, referred to as early-ons t AD [25]. AD is the most commo form f dementia and is
characterise by accumulation f abnormal neuritic plaques composed of β-amyloid
peptide, together with eurofibrillary tangles of misfolded tau protein, in the brain of AD
patients [26,27]. The causes of AD have yet t be fully elucidated, with a myriad of ge etic
and en ironmental factors ssociated with the developm nt of this disorder [28]. However,
oxidative stress is thought to be an important factor in disease pathogenesis, reportedly
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preceding the appearance of neurofibrillary tangles and senile plaques, although the origin
of the oxidative stress is uncertain [29]. In view of the potent antioxidant propensity of
CoQ10, studies have been undertaken to assess the endogenous CoQ10 status of patients
with AD. However, no evidence of a deficiency in the circulatory level of this isoprenoid
has so far been reported [30,31]. Nonetheless, a population-based prospective cohort
study by Yamagishi et al. [32] has suggested that serum CoQ10 levels may be a predictor
rather than a biomarker of dementia. In vitro studies using human vein endothelial cells
(HVEC) have indicated the potential therapeutic potential of CoQ10 supplementation in
preventing the harmful effects of β-amyloid deposition in the early asymptomatic stages
of AD, which may delay the progression of the neuropathology [33]. Pre-treatment of the
HVEC with CoQ10 prevented β-amyloid-induced cellular toxicity and oxidative injury
by inhibiting β-amyloid trafficking and accumulation in the mitochondria [33]. In a rat
model of AD, an injection of β-amyloid was found to significantly increase the serum level
of malondialdehyde, an end product of lipid peroxidation, and total oxidant levels. CoQ10
supplementation was found to significantly reverse these consequences and increase the
total antioxidant capacity of the serum [34]. The results of this study have indicated the
potential of CoQ10 to offer some protection against the oxidative stress associated with
AD. However, in a randomised clinical trial in which 70 patients with mild to moderate
AD were treated with CoQ10 (400 mg; three times/day) for 16 weeks, no clinical benefit
or significant effect on the CSF biomarkers for AD (amyloid-beta and tau protein levels)
were reported [35]. To date, no large clinical studies have assessed the cognitive effect
of CoQ10 supplementation in AD; however, clinical studies with the CoQ10 analogue
idebenone have reported modest cognitive and behavioural improvements in patients
following supplementation [36,37]. There were, however, drop-out rates as high as 71%
in these studies. A subsequent, one-year, multicentre, double-blind, placebo-controlled,
randomised clinical trial of 536 AD patients found that idebenone treatment (120, 240 or
360 mg, three times a day) failed to slow cognitive decline in AD [38].
Parkinson’s disease: Parkinson’s disease (PD) is a chronic and progressive neurode-
generative disorder characterised by proteinaceous intraneuronal Lewy body formation
and striatal dopamine depletion in the substantia nigra of the mid-brain [39]. This disease,
which is the second most common neurodegenerative disorder after AD, with an incidence
of approximately 13.4 per 100,000, is most commonly diagnosed in people over the age
of 60, although 4% of cases present under the age of 50 [40]. Patients with PD commonly
experience motor symptoms, such as bradykinesia, tremor, muscle stiffness (rigidity) and
postural instability [41]. Whilst the preponderance of cases of PD are spontaneous or
idiopathic, a genetic origin for this disease has also been reported in approximately 15% of
patients [42]. Evidence for the involvement of MRC in the pathogenesis of PD emerged
in the early 1980s with reports of Parkinsonian-like presentation of intravenous users
of the synthetic drug, 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (MPTP), which was
also known as synthetic heroin [43]. MPTP is converted into the neurotoxin, 1-methyl-
4-phenylpyridinium (MPP+) via a reaction catalysed by monoamine oxidase-B (MAO-B)
enzyme. MPP+ was found to induce a Parkinsonian-like state in rats and primates by
the inhibition of MRC complex I activity [43]. A subsequent study by Schapira et al. [44]
reported evidence of decreased MRC complex I activity in post-mortem brain samples from
PD patients. At present, the origin of the cerebral MRC complex I deficiency in PD has yet
to be fully elucidated, although oxidative stress is thought to be an important contributory
factor [45]. Together with evidence of impaired MRC complex I activity, a deficiency in
cerebral CoQ10 status has also been reported in PD patients [23]. A decrease in CoQ10
status has also been reported in both the plasma and platelets of PD patients [46,47]. The
cause of the decrease in CoQ10 status associated with PD is at present uncertain, although
it is thought to be associated with the increase in oxidative stress associated with this con-
dition, which may either increase the catabolism of CoQ10 or inhibit the enzymes involved
in its biosynthesis [48]. Although the functional consequences of a CoQ10 deficiency in
PD are at present unclear, a decrease in CoQ10 status would be expected to contribute to
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disease pathophysiology by compounding MRC function, as well as compromising cellular
antioxidant status. A number of clinical studies have examined the therapeutic potential of
CoQ10 supplementation in the treatment of PD.
In a phase II clinical trial conducted by Schults et al. [49], oral CoQ10 supplementation
was found to reduce the functional decline of patients with early-stage PD. In this study,
patients were randomly assigned to a placebo or to a CoQ10 treatment group (300, 600 or
1200 mg/day). Disease progression was then determined using the Unified Parkinson’s
Disease Rating Scale (UPDRS) at one, four, eight, twelve and sixteen months. The UPDRS
assesses the mental and motor capacity of patients, as well as their ability to complete daily
living activities. Following eight months of treatment with CoQ10 (300 and 600 mg/d),
the mean total UPDRS score of patients was similar. However, it was lower than that of
the placebo group, suggesting that CoQ10 supplementation was in some way slowing the
disease progression of PD. However, the UPDRS scores of PD patients receiving 1200 mg/d
of CoQ10 were not significantly lower than the 300 and 600 mg/d CoQ10 treatment groups,
suggesting that there may be a dosage threshold for the gastrointestinal absorption (GI) of
CoQ10 into the circulatory system. The efficiency of absorption of CoQ10 formulations has
been reported to decrease as the dosage increases, with a suggested GI absorptional block
above 2400 mg [50]. A subsequent phase III clinical trial involving six hundred patients
was undertaken with PD patients receiving CoQ10 dosages of 1200 or 2400 mg/d [51].
Despite 1200 mg/d being the highest dosage used in the previous study, the mean change
in UPDRS score of treated patients was not found to be significantly lower than that of
the placebo group, and the researchers concluded that since CoQ10 appeared to show
no apparent clinical benefit, they could not recommend its use in the treatment of early-
stage PD. The contrasting findings of the clinical studies by Shults et al. [49] and Beal
et al. [51] may reflect the broad range of sporadic PD patients used in the two clinical trials,
with the heterogeneous patient populations contributing to their contradictory findings.
Furthermore, no assessment of an underlying CoQ10 deficiency was determined in the
PD patients prior to commencing CoQ10 supplementation in the study by Beal et al. [51],
which may explain the limited therapeutic potential of CoQ10 reported.
Amyotrophic Lateral Sclerosis: Amyotrophic lateral sclerosis (ALS), otherwise known
as motor neuron disease, is a progressive disorder characterised by the degeneration of
upper and lower motor neurons within the brain and spinal cord, resulting in the loss of
muscle control. Most cases of ALS are sporadic, although there is a familial form, with
a typical age of onset at 60 years or 50 years, respectively. A hallmark of ALS is the de-
velopment of ubiquinated protein aggregates within the motor neurons, resulting in the
degeneration of the latter. Although the cause of aggregate formation is not completely
understood, mitochondrial dysfunction and oxidative stress have been implicated [52,53].
Although supplemental CoQ10 or its synthetic analogue, MitoQ, prolonged survival in
a mouse model of ALS [54,55], a Phase II trial supplementing 2700 mg CoQ10/day for 9
months in 185 ALS patients found insufficient benefits to warrant a Phase III study [56].
Stroke: Stroke, by definition, is a disorder in which the normal blood supply to the
brain is disrupted; this may result from blockage of a blood vessel by a blood clot (occlusive
stroke) or as a result of a blood vessel rupture (haemorrhagic stroke). Mitochondrial
dysfunction and oxidative stress have been regarded as hallmarks of ischemia/reperfusion-
induced neuronal death following stroke [57,58]. In this regard, Simani et al. [59] found
serum CoQ10 levels to be significantly depleted in patients following acute stroke and to
correlate with clinical neurological outcomes. However, a randomised controlled study
supplementing CoQ10 in acute stroke patients comprised too few patients (22 CoQ10,
22 placebo) and too low a dosage regime (300 mg/day for 4 weeks) to make a definitive
conclusion re efficacy [60].
Multiple system atrophy: Multiple system atrophy (MSA) is an example of one of
the less common neurological disorders, with an age of onset typically in the range of
50–60 years. This disorder results from progressive degeneration of neurons and glia,
with subsequent dysfunction of the autonomic nervous system. MSA has been included
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in the present review since its pathogenesis has been linked to the dysfunction of an
enzyme (COQ2; 4-parahydroxybenzoate:polyphenyltransferase) in the CoQ10 synthetic
pathway. Several studies have reported a reduction in plasma or post-mortem brain
tissue. Thus, in a series of 44 MSA patients, Mitsui et al. [61] found a significant reduction
in the mean plasma CoQ10 level of approximately 30% compared to controls. Barca
et al. [62] found CoQ10 levels to be significantly depleted (by 40%) in post-mortem cerebellar
tissue from MSA patients, compared to controls. In addition, in a study using induced
pluripotent stem cell (iPSC)-derived neurons, CoQ10 levels were significantly reduced in
MSA patients, particularly those with COQ2 functional variants [63]. To date, there have
been no randomised controlled trials of CoQ10 in MSA.
Ophthalmic disorders: Age-related disorders of the eye include glaucoma, macular
degeneration and cataracts. The eye is exposed to high levels of UV radiation and its
associated free radical-induced oxidative stress; in addition, the retina is one of the body’s
most metabolically active tissues, with concomitant requirements for energy production and
antioxidant protection. Thus, all of the above factors are of relevance to the metabolic roles
of CoQ10 and its potential in the treatment of these age-related eye disorders. Glaucoma
is a common disorder, which can result in loss of vision if not treated sufficiently early.
Glaucoma results from damage to the optic nerve, typically (but not always) resulting from
an increase in intraocular pressure, in turn resulting from fluid accumulation. Glaucoma
can occur at any age but is most common in individuals aged over 70 years. A number of
factors may contribute towards the degeneration of the optic nerve, including mitochondrial
dysfunction and subsequent oxidative stress in retinal ganglion cells [64], suggesting a
potential role for supplemental CoQ10 in the treatment of this disorder. Thus Qu et al. [65]
found CoQ10 levels in retina and choroid from younger (<30 years) and older (>80 years)
decreased by approximately 40% with age. The method of CoQ10 administration to the eye
then needs to be addressed. Topically applied CoQ10 has poor intraocular penetration and
subsequent bioavailability, partly because of its molecular characteristics and partly through
the action of the P-glycoprotein (P-gp) efflux pump present in the corneal epithelial cells,
which extrudes CoQ10 out of cells. However, increased corneal penetration and intraocular
absorption of CoQ10 can be achieved by topical co-administration of CoQ10 with alpha-
tocopherol, a known inhibitor of the P-glycoprotein pump [66]. Macular degeneration
is a disorder characterised by the loss of vision in the central part of the visual field,
again linked to mitochondrial dysfunction and oxidative stress in affected retinal pigment
epithelial cells. Macular degeneration typically develops in individuals aged 60 years
and above. In a randomised controlled trial, patients with macular degeneration were
treated with a combination of CoQ10, acetyl-L-carnitine and n-3 fatty acids over a twelve-
month period [67]. Measured parameters of visual function included visual field mean
defect, visual acuity (Snellen chart and ETDRS chart), foveal sensitivity as measured by
perimetry and fundus alterations as evaluated according to the criteria of the International
Classification and Grading System for AMD; at the end of the study period, all four of
these parameters showed significant improvement in treated patients compared to placebo.
Cataracts result in a loss of vision caused by the development of opacity in the lens,
in turn resulting from denaturation of crystallin protein components of the lens induced
by oxidative stress. Cataracts typically develop in individuals aged 50 years and above,
affecting more than 50% of people aged 80 years. Kernt et al. [68] showed that the incubation
of human lens epithelial cells with CoQ10 significantly reduced light-induced cell damage.
A combination of CoQ10 and alpha-tocopherol has been used to reduce post-operable
corneal damage after cataract surgery [69,70].
5. Why Have Clinical Trials of CoQ10 in Neurological Disorders Been Disappointing?
Studies using animal model systems of a number of neurodegenerative disorders
have shown promising evidence of benefit following supplementation with CoQ10. Thus,
the administration of CoQ10 has been shown to be beneficial in paraquat-induced or
MPTP-induced murine models of Parkinson’s disease by improving behaviour, reducing
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oxidative stress or preventing loss of dopamine [71–73]. Similarly, supplementary CoQ10
reduced oxidative stress, beta-amyloid deposition and cognitive performance in transgenic
mouse models of Alzheimer’s disease [74]. In addition, supplementary CoQ10 significantly
improved life span in a transgenic mouse model of familial ALS [54]. It is also of note
that supplemental CoQ10 prevented the decline in mitochondrial function associated with
normal ageing in mice [75].
Mitochondrial dysfunction and oxidative stress have been implicated in the patho-
genesis of Parkinson’s disease [76], Alzheimer’s disease [77], ALS [78] and stroke [79]. In
clinical studies, CoQ10 levels have been found to be depleted in both the blood and brain
cortex tissue of Parkinson’s disease patients [23]. Depleted levels of CoQ10 in blood are
associated with an increased risk of developing Alzheimer’s disease [32]. High levels of
oxidised CoQ10 (associated with increased oxidative stress) were reported in patients with
ALS [80].
On the basis of the cellular functions of CoQ10 and the results of the various studies
outlined above, there is, therefore, a clear rationale for clinical studies supplementing
CoQ10 in age-related neurodegenerative disorders. However, the outcomes of clinical
trials supplementing CoQ10 in various neurological disorders, most notably Alzheimer’s
disease, Parkinson’s disease and ALS, have been surprisingly disappointing. Thus, phase II
or Phase III trials of high-dose CoQ10 in Alzheimer’s disease (1200 mg/day for 16 weeks),
Parkinson’s disease (1200–2400 mg/day for 16 months) or ALS (2700 mg/day for 9 months)
failed to slow the progression of these disorders, respectively [35,51,56]. A randomised
controlled study supplementing CoQ10 in acute stroke patients comprised too few patients
(22 CoQ10, 22 placebo) and too low a dosage regime (300 mg/day for 4 weeks) to make a
definitive conclusion re efficacy [60]. In rationalising the outcomes from the above studies,
a number of issues need to be considered.
Firstly, was the supplementary CoQ10 sufficiently absorbed from the digestive tract
into the bloodstream. Because of the extreme hydrophobicity of the CoQ10 molecule,
orally administered CoQ10 has a low bioavailability. Briefly, following transit through
the stomach, CoQ10 is subject to micellisation within the duodenum, which facilitates the
transport of CoQ10 to the intestinal villi prior to its absorption by enterocytes. CoQ10
is absorbed into enterocytes via a process of passive facilitated diffusion; the facilitator
molecule for CoQ10 has not been definitely characterised, but the cholesterol transporter
NPC1L1 (Niemann-Pick C1 Like 1) has been suggested as a potential candidate [81,82].
CoQ10 is then incorporated into chylomicrons, which are released into the distal abdominal
lymph duct, where they can then enter the systemic blood circulation via the subclavian
vein. Chylomicrons in the circulation are taken up by the liver where CoQ10 is then re-
packaged into lipoprotein particles, principally, LDL (low density lipoprotein) and VLDL
(very low-density lipoprotein) cholesterol, with a relatively small amount of CoQ10 being
associated with HDL (high-density lipoprotein) cholesterol [83]. Estimates of exogenous
CoQ10 bioavailability following the above process have typically been in the order of 1–5%.
Of the various factors potentially influencing exogenous CoQ10 bioavailability, supple-
ment formulation is a key factor. Thus, the comparative study in human subjects carried out
by Lopez-Lluch and colleagues [84] demonstrated the importance of CoQ10 supplement
formulations in maximising absorption. The bioavailability of 7 different formulations of
CoQ10 (differing by: CoQ10 crystal dispersion status, type of carrier oil, the composition of
other excipients and CoQ10 oxidation state) were administered to 14 healthy individuals in
a single 100 mg dose using a crossover/washout protocol [83]. The bioavailability of the
different formulations was quantified as AUC (area under the curve) following 48 h after
administration. A salient point to note from this study is the difference in bioavailability
between samples 01 and 02. Both samples contained 100 mg CoQ10 in identical ubiquinone
form in a soy carrier oil with similar excipient content and capsule specification. Sample 01
(Bio-Quinone, Pharma Nord) had been subjected to a patented thermal crystal dispersion
process, whilst sample 02 had not been treated in this manner. The respective mean AUC
and Cmax (concentration maximum) values in the Lopez-Lluch study were 28.0 mg/L/48 h
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and 1.07 mg/L for sample 01, and 6.89 mg/L/48 h and 0.33 mg/L for sample 2, respec-
tively. The failure to subject crystalline CoQ10 to crystal dispersion, therefore, reduced
its bioavailability by approximately 75%. The second point of note relates to the relative
bioavailability of the ubiquinone and ubiquinol forms of CoQ10. For the ubiquinol form
(sample 05), the AUC and Cmax values were 14.8 mg/L/48 h and 0.49 mg/L, respectively.
Thus, the AUC for CoQ10 in ubiquinol form was approximately twice that for ubiquinone
form, which had not been subjected to thermal crystal dispersion (sample 02), but was only
52% of that for ubiquinone that had been subject to thermal crystal dispersion (sample 01).
These data, therefore, demonstrate:
(i) The importance of CoQ10 crystal dispersion since the failure to disperse CoQ10
crystals to single molecules reduces the bioavailability of CoQ10 by approximately
75%;
(ii) That the relative bioavailability of ubiquinone and ubiquinol forms of CoQ10 depends
on its CoQ10 crystal dispersion status and carrier oil/excipient composition.
The above analysis is reproduced from the paper by Mantle and Dybring [83].
Thus, in clinical studies, the extent of supplement absorption should always be quanti-
fied via one of the standard HPLC-based methods [85]. Normal plasma levels of CoQ10
are in the range 0.5–1.5 mcg/mL [86]. In the Phase III clinical trial of CoQ10 in Parkin-
son’s disease, the administration of 1200 mg/day CoQ10 raised the mean plasma level
to 5.80 mcg/mL after 16 months, whilst a dose of 2400 mg/day raised the mean plasma
CoQ10 levels to 9.94 mcg/mL [51]. In the Phase II trial of CoQ10 in ALS, supplementation
with CoQ10 at 1800 mg/day raised the mean plasma level to 4.66 mcg/mL after 9 months,
and a dose of 2700 mg/day raised the mean plasma CoQ10 level to 5.96 mcg/mL [56]. In
the above studies in Parkinson’s disease or ALS, it is, therefore, evident that supplementary
CoQ10 substantially raises circulatory levels of CoQ10. However, in a small-scale ran-
domised control trial of CoQ10 (1200 mg/day for 16 weeks) in Alzheimer’s disease, which
provided no cognitive benefit, changes in blood CoQ10 levels following supplementation
were not measured [35].
The second issue to consider is whether the supplementary CoQ10 was able to cross
the blood–brain barrier, and thirdly, how the CoQ10 was distributed between and within
brain cells. The latter issues remain largely unknown quantities in human subjects; whilst
there is evidence that supplementary CoQ10 can penetrate the blood–brain barrier in
animal species, this has yet to be established in humans [87]. In this regard, synthetic
analogues of CoQ10, such as idebenone or mitoquinone, have been developed with the
intention of improving blood–brain barrier penetration or mitochondria-specific targeting,
although the efficacy and safety of such compounds have yet to be fully established in
clinical studies [88]. A key issue, therefore, is to determine how CoQ10 may access the
blood–brain barrier in humans. In this regard, a recent study by Wainwright et al. [89] using
a model system based on porcine brain endothelial cells identified lipoprotein-associated
CoQ10 transcytosis in both directions across the in vitro BBB. The uptake of CoQ1 the via
the SR-B1 (Scavenger Receptor) and the RAGE (Receptor for Advanced Glycation End
products) receptors was comparable to the efflux of CoQ10 via the LDLR (Low-Density
Lipoprotein Receptor) transporter, which resulted in no “net” transport of CoQ10 across
the BBB. When a CoQ10 deficiency was induced in the model (using p-aminobenzoic acid)
treatment, the tight junctions of the BBB were disrupted, and CoQ10 “net” transport to
the brain side was increased. Within this area of research, a study by Park et al. [90] is
of particular note. In this study, using a rat model of Parkinson’s disease, continuous
intrastriatal delivery of low-dose CoQ10 (some four orders of magnitude lower than orally
administered CoQ10) showed significant benefits in terms of dopaminergic neuronal loss,
as well as behavioural benefits. Whether such an invasive regime could be used for the
treatment of Parkinson’s patients is currently an unresolved question. To date, only two
randomised controlled trials involving intrastriatal intervention (with agents other than
CoQ10) in Parkinson’s disease patients have been reported, both of which involved surgical
transplantation, and both of which provided no significant symptomatic benefit [91,92].
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With regard to the transport of substances into the brain, a point to consider relates
to a difference in dosing regimens between the Phase II and Phase III trials of CoQ10 in
Parkinson’s disease. In the Phase II study, CoQ10 in daily doses of 300, 600 or 1200 mg
were administered to Parkinson’s disease patients, resulting in a significant slowing of
functional decline [49]. In the Phase III study, daily doses of CoQ10 (1200 or 2400 mg)
were administered to Parkinson’s disease patients, together with a daily dose of 1200 IU
of vitamin E; there was no evidence of significant symptomatic benefit, in contrast to the
outcome of the Phase II study [51]. As with the transport of CoQ10 into the brain, the
transport of vitamin E into the brain is also poorly understood [93]; the question, therefore,
arises as to whether co-administration of a high dose of vitamin E could have inhibited
access to the brain for CoQ10, for example via competition for shared lipoprotein or other
carrier types.
With regard to the intracellular transport of CoQ10, this process, whether in brain
tissue or in other tissues, is currently not well understood. Within cells, a transport mech-
anism must exist to facilitate the transport of CoQ10 between the subcellular organelles
where endogenous CoQ10 is synthesised and those where it is utilised, as well as the sub-
cellular distribution of exogenous CoQ10. Several such mechanisms have been proposed,
including Golgi-derived vesicular transport in plant tissues [94] and the transport of CoQ10
via the protein saposin B in human tissues [95].
Patient selection is another potential confounding factor re bioavailability. For example,
it is known that Parkinson’s disease is etiologically heterogeneous; thus, mutations in the
PINK1 gene (a known cause of Parkinson’s disease) affect the ability of mitochondria to
utilise CoQ10 in the energy generation process, so it follows that supplementing with
CoQ10 would not benefit this type of Parkinson’s disease patients. In this regard, clinical
trials comprising genetically stratified subgroups of Parkinson’s disease patients who might
benefit from supplementation with CoQ10 have been proposed by Prasuhn et al. [96], and
this approach may lead to more successful outcomes using this type of therapeutic strategy.
In addition, the comparative bioavailability clinical study carried out by Lopez-Lluch and
colleagues [84] demonstrated the wide inter-individual ability of subjects to absorb a given
formulation of CoQ10; in particular that there may be groups of patients with restricted
ability to absorb this compound irrespective of formulation type.
Finally, it is useful to compare the outcome of supplementing CoQ10 in the above
disorders with a neurological disorder in which CoQ10 supplementation has been clin-
ically successful, namely cerebellar ataxia. Cerebellar ataxia is an autosomal recessive
disorder resulting from a primary CoQ10 deficiency (resulting from genetic defects in the
CoQ10 biosynthetic pathway). This condition typically manifests in childhood or early
adulthood [97]. The early identification of a CoQ10 deficiency in patients with cerebellar
ataxia is very important, as patients can show remarkable clinical improvement following
CoQ10 supplementation when it is administered at an early stage of the disease. This is
illustrated by the clinical studies of Musumeci et al. [98] and Lamperti et al. [99], which
reported a significant improvement in the cerebellar function in children or young adults
following supplementation with CoQ10 (300–3000 mg/day). The successful outcome of
such studies implies that supplemental CoQ10 was able to cross the blood–brain barrier
in human subjects. The success or otherwise of CoQ10 supplementation in neurological
disorders may, therefore, depend on whether the condition is a primary or secondary
deficiency and the stage of disease at which supplementation is attempted. With regard to
the safety of CoQ10 supplementation, CoQ10 is generally well tolerated, with no serious
adverse events reported in long term use. Furthermore, there are no known toxic effects
associated with CoQ10 supplementation, and CoQ10 cannot be overdosed. However, very
rarely, individuals may experience mild gastrointestinal disturbance following CoQ10
supplementation, although this does not appear to be dose-related [100].
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6. Summary
(i) Brain tissue is subject to characteristic changes associated with the ageing process.
There is an increased risk of developing particular neurological disorders with increasing
age, notably Parkinson’s disease, Alzheimer’s disease, ALS and stroke.
(ii) There is a considerable body of evidence in the published literature implicating
mitochondrial dysfunction and oxidative stress in the pathogenesis of the above disorders.
There is, therefore, a rationale for the involvement of CoQ10 in the pathogenic mechanism
underlying these disorders, given the key role played by CoQ10 in normal mitochondrial
function and its role as a major endogenous antioxidant.
(iii) Although a relatively small amount of CoQ10 is obtained from the normal diet,
most of the body’s daily CoQ10 requirement is derived from endogenous synthesis, which
takes place in most tissues. As people age, the capacity of the body to produce CoQ10
declines, particularly over the age of 50 years. The decline in CoQ10 synthetic capacity,
therefore, mirrors the increased risk of developing the neurological disorders outlined
above.
(iv) Although studies supplementing CoQ10 in animal models of the above disorders
showed significant symptomatic benefit, clinical studies supplementing CoQ10 have been
surprisingly disappointing in outcome, most notably in patients with Parkinson’s disease
or ALS.
(v) The question, therefore, arises as to why such clinical studies have been unsuccess-
ful. A number of factors may be involved, but particularly whether CoQ10 is able to cross
the blood–brain barrier; although this has been demonstrated in brain tissue from several
animal species, this has yet to be confirmed in humans.
(vi) Whether exogenous CoQ10 can cross the blood–brain barrier in humans, therefore,
remains an outstanding issue and area for future research; in particular, whether the
binding of CoQ10 to LDL/VLDL carriers is a necessary requirement for CoQ10 to access
the blood–brain barrier.
(vii) Another relevant issue requiring further research is the mechanism(s) by which
exogenous CoQ10 is distributed within brain tissue cells once it has crossed the blood–brain
barrier; this is also the case for endogenously synthesised CoQ10 and for tissues other than
brain tissue.
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